Amphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year Performance [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
Adjusted Non-GAAP Net Income : $46.9 million for Q4 2023, reflecting a more comprehensive view of profitability. GAAP Diluted EPS : $0.68 for Q4 2023, showing earnings growth per share. Product Revenues : Significant contributions from glucagon and Primatene MIST. Operating Cash Flow : $183.5 million for the full year, indicating strong cash generation. Pipeline Development : Multiple ANDAs and biosimilar products in development targeting markets worth billions. Warning! GuruFocus has detected 2 Warning Sign with AMPH. On February 28, 2024, Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) released its 8-K filing , revealing a significant uptick in revenue and earnings for the fourth quarter and full year ended December 31, 2023. The company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API, reported a 32% increase in net revenues for the quarter, amounting to $178.1 million, and a 29% increase for the full
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024Accesswire
- Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growth [Yahoo! Finance]Yahoo! Finance
- Pharvaris appoints David Nassif as chief financial officer [Seeking Alpha]Seeking Alpha
- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 2/28/24 - Beat
AMPH
Sec Filings
- 5/1/24 - Form 144
- 4/19/24 - Form DEFA14A
- 4/12/24 - Form ARS
- AMPH's page on the SEC website